“…Our meta-regression analysis (6) involved 30 trials including 149,407 randomized patients: 9 actively controlled trials (MIDAS (8), CAPPP (9,73), NICS (10), STOP2 (11), INSIGHT (12,74), NORDIL (13), ALLHAT/ Dox (14), VHAS (26), and UKPDS (16,75)); the HOT trial (76), which investigated 3 levels of diastolic blood pressure (96)). Seven studies were excluded for the following reasons: fewer than 100 patients had been randomized (97−99), follow-up was less than 2 years (100, 101), insufficient information was published on achieved SBP (HDFP (102, 103)) or non-fatal outcomes (CASTEL (104)), and/or randomization took place between usual and referred care (CASTEL (104) and HDFP (102,103)). …”